Advisories For Registrants
June 17th, 2024
Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
June 10th, 2024
Important Safety and Efficacy Information on ALBRIOZA (sodium phenylbutyrate and ursodoxicoltaurine) – Market Withdrawal and Continued Restricted Access
June 6th, 2024
Importation of USA-authorized Carbamazepine Extended-Release Tablets, USP 200 mg and 400 mg due to the current shortage of Canadian-authorized carbamazepine
Advisories For The Public
August 5th, 2024
Expanded recall: ratio-ECTOSONE (TEVA-ECTOSONE) 0.1% regular lotion and 0.05% mild lotion recalled due to an impurity that may pose health risks
August 5th, 2024
JAMP Digoxin 0.0625 mg and 0.125 mg tablets recalled due to possible incorrect dose, which may pose health risks
July 29th, 2024
Various multivitamins and supplements distributed across Canada are being recalled because they may contain metal fibres
July 26th, 2024
Incorrect dosing information on the “SAVE ME” instructional card in the Naloxone Take Home Kit by Canadian Hospital Specialties Ltd
June 17th, 2024
Dianeal PD4 2.5% Dextrose and Physioneal 40 2.27% Glucose peritoneal dialysis solutions recalled due to risk of leakage at connection site
June 10th, 2024
Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone tablets recalled due to data integrity concerns
Do you provide pharmacy services for veterinarians or pet owners? If so, please note the following important information regarding federal regulation changes that may apply to you or your practice.
Regulatory changes to federal Food and Drug Regulations, meant to ensure the responsible use of antimicrobials in animals, may affect you if:
- You import active pharmaceutical ingredients (APIs) that are set out on List A: List of Certain Antimicrobial Active Pharmaceutical Ingredients; and/or
- You are a pharmacy professional who compounds antimicrobial drugs using APIs on List A: List of Certain Antimicrobial Active Pharmaceutical Ingredients for animal use.
The increased oversight on APIs for veterinary use require:
- manufacturing according to good manufacturing practices (GMPs);
- persons who fabricate, import, package, label and test active pharmaceutical ingredients (APIs) for veterinary use to hold a drug establishment license (DEL); and
- pharmacists, veterinarians or those compounding a drug under the supervision of a licensed veterinarian to hold a drug establishment license (DEL) when importing medically important antimicrobials that are on List A: List of Certain Antimicrobial Active Pharmaceutical Ingredients.
Therefore, as of May, 17 2018, you may need to:
- Be inspected by Health Canada,
- Comply with GMP, and/or
- Obtain a DEL (see below regarding transition period).
Health Canada has established a 14 month transition period to obtain a DEL. If you were already performing activities with respect to API for veterinary use before May 17, 2018, then you must submit a complete DEL application by July 17, 2019. If you were not already undertaking these activities before May 17, 2018, then you cannot conduct licensable activities until you obtain an appropriate DEL. There is no transition period for meeting GMP requirements – they must be met by May 17, 2018.
If you are a manufacturer, importer, or compounder of antimicrobial drugs for veterinary use that contain an active pharmaceutical ingredient on List A, you will need to report annual sales data to Health Canada. This means you will need to collect data throughout 2018 and report by March 31, 2019.
Resources
Health Canada has made available the following resources:
- Health Canada Webinar Session 1: An introduction to the new requirements under the Food and Drug Regulations affecting industry and health care practitioners who compound veterinary drugs
- Recording
- PowerPoint (PDF)
- Health Canada Webinar Session 2: How to submit an application or an amendment to a Drug Establishment License for veterinary active pharmaceutical ingredients
- Recording
- PowerPoint (PDF)
- Drug Establishment License Q&As – Anti-Microbial Resistance Regulatory Amendment
For any questions, please contact Health Canada at hc.vamsr-vamvr.sc@canada.ca using the subject line “AMR Info Request.”